MX2023007680A - Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. - Google Patents

Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Info

Publication number
MX2023007680A
MX2023007680A MX2023007680A MX2023007680A MX2023007680A MX 2023007680 A MX2023007680 A MX 2023007680A MX 2023007680 A MX2023007680 A MX 2023007680A MX 2023007680 A MX2023007680 A MX 2023007680A MX 2023007680 A MX2023007680 A MX 2023007680A
Authority
MX
Mexico
Prior art keywords
methods
gemcitabine
treatment
maintenance therapy
bladder cancer
Prior art date
Application number
MX2023007680A
Other languages
English (en)
Inventor
Christopher Cutie
Dennis Giesing
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2023007680A publication Critical patent/MX2023007680A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para tratar carcinomas uroteliales del tracto inferior que comprenden administrar gemcitabina continuamente y localmente a la vejiga de un individuo en una terapia de inducción y/o terapia de mantenimiento.
MX2023007680A 2017-11-08 2020-07-13 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. MX2023007680A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762583394P 2017-11-08 2017-11-08

Publications (1)

Publication Number Publication Date
MX2023007680A true MX2023007680A (es) 2023-07-07

Family

ID=66439297

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004771A MX2020004771A (es) 2017-11-08 2018-11-07 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
MX2023007680A MX2023007680A (es) 2017-11-08 2020-07-13 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020004771A MX2020004771A (es) 2017-11-08 2018-11-07 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Country Status (18)

Country Link
US (3) US10792297B2 (es)
EP (1) EP3706763A4 (es)
JP (2) JP2021502347A (es)
KR (1) KR20200085822A (es)
CN (1) CN111787926A (es)
AU (1) AU2018366106A1 (es)
BR (1) BR112020008700A2 (es)
CA (1) CA3081839A1 (es)
DO (1) DOP2023000155A (es)
EA (1) EA202091143A1 (es)
IL (2) IL302714A (es)
JO (1) JOP20200124A1 (es)
MA (1) MA50581A (es)
MX (2) MX2020004771A (es)
PE (1) PE20210041A1 (es)
PH (1) PH12020550587A1 (es)
SG (1) SG11202003950WA (es)
WO (1) WO2019094517A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
WO2024092159A1 (en) * 2022-10-28 2024-05-02 Taris Biomedical Llc Methods of treating bladder cancer with gemcitabine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177362A1 (en) 2009-06-26 2012-02-28 Taris Biomedical Inc Solid drug tablets for implantable drug delivery devices
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
HUE053888T2 (hu) 2009-12-17 2021-07-28 Taris Biomedical Llc Intravezikálisan tolerálható beültethetõ eszköz
NZ708506A (en) 2010-06-02 2016-08-26 Abraxis Bioscience Llc Methods of treating bladder cancer
SI2600800T1 (sl) 2010-08-05 2021-03-31 Taris Biomedical Llc Naprava za dovajanje zdravila preko sečevodnega stenta in komplet
KR20140048086A (ko) 2011-02-04 2014-04-23 타리스 바이오메디컬 인코포레이티드 저 용해성 약물의 제어 방출을 위한 이식가능한 디바이스
CA2868431A1 (en) 2012-03-29 2013-10-03 Altor Bioscience Corporation Methods for treating neoplasia
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX365688B (es) 2012-08-31 2019-06-11 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
WO2014138214A1 (en) 2013-03-05 2014-09-12 Taris Biomedical, Inc. Drug delivery devices and methods for controlled drug release through device orifice
NZ711416A (en) 2013-03-15 2018-02-23 Taris Biomedical Llc Drug delivery devices and methods for drug delivery
MX2015012367A (es) 2013-03-15 2016-05-31 Taris Biomedical Llc Dispositivos de suministro de farmacos con un componente permeable al farmaco y metodos.
DE102013103986A1 (de) 2013-04-19 2014-10-23 B. Braun Avitum Ag Rezirkulationsvorrichtung eines extrakorporalen Blutbehandlungsgeräts
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
PL3113782T3 (pl) * 2014-03-06 2023-01-23 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza moczowego gemcytabiną
WO2015200752A1 (en) 2014-06-26 2015-12-30 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
US10894150B2 (en) 2015-04-23 2021-01-19 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
JP2019514970A (ja) 2016-05-06 2019-06-06 タリス バイオメディカル エルエルシー 下部尿路上皮がんを処置する方法
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
US11464734B2 (en) 2018-08-01 2022-10-11 Taris Biomedical Llc Methods of treating overactive bladder using trospium

Also Published As

Publication number Publication date
US20210085705A1 (en) 2021-03-25
US20230321129A1 (en) 2023-10-12
MA50581A (fr) 2020-09-16
EP3706763A4 (en) 2021-08-11
IL302714A (en) 2023-07-01
IL274343B2 (en) 2023-10-01
IL274343A (en) 2020-06-30
BR112020008700A2 (pt) 2020-10-27
PE20210041A1 (es) 2021-01-08
US10792297B2 (en) 2020-10-06
JP2024009888A (ja) 2024-01-23
JP2021502347A (ja) 2021-01-28
DOP2023000155A (es) 2023-12-29
PH12020550587A1 (en) 2021-04-26
EP3706763A1 (en) 2020-09-16
WO2019094517A1 (en) 2019-05-16
US20190175637A1 (en) 2019-06-13
CA3081839A1 (en) 2019-05-16
JOP20200124A1 (ar) 2020-05-20
AU2018366106A1 (en) 2020-05-14
KR20200085822A (ko) 2020-07-15
IL274343B1 (en) 2023-06-01
CN111787926A (zh) 2020-10-16
MX2020004771A (es) 2020-10-19
EA202091143A1 (ru) 2020-07-30
SG11202003950WA (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
IL261008B1 (en) Combined immunotherapy and cytokine control therapy for cancer treatment
WO2016025635A3 (en) Combination therapy for treating cancer
MX2016004489A (es) Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos.
MX2023006304A (es) Administracion de celulas t dise?adas para tratamiento de canceres en el sistema nervioso central.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2019011148A (es) Metodos de tratamiento.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
WO2016043874A3 (en) Combination therapy for treating cancer
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX2017015896A (es) Agente anticancerigeno.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
IL275517A (en) Combined methods and treatment of cancer
IL279591A (en) Cancer treatment methods using combination therapy
MX2019003751A (es) Proteina terapeutica.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
IL275913A (en) Methods and combined treatment for cancer treatment